Shandong Xinhua Pharmaceutical Company Limited Class A

As of March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H carries a market capitalization of 12.53B, placing it among publicly traded companies globally. Its enterprise value stands at 12.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shandong Xinhua Pharmaceutical Company Limited Class H's next confirmed earnings release is scheduled for October 28, 2026.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H has 1.97B shares outstanding.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H trades at a trailing price-to-earnings ratio of 22.43. The price-to-sales ratio is 0.85, and the price-to-book ratio stands at 2.06.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H trades at an EV/EBITDA multiple of 26.23 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.98B versus a market cap of 12.53B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H maintains a current ratio of 1.76, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.39, indicating elevated leverage, while an interest coverage ratio of 9.99 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H posted a return on equity (ROE) of 6.60, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.09 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.24, useful for judging operating efficiency across full business cycles. The company generates approximately 1.42M in revenue per employee across its workforce of 7,268.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.90 indicates how many times Shandong Xinhua Pharmaceutical Company Limited Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H recorded 92.33M in income tax expense. That works out to an effective tax rate of 18.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 494.42M, leaving 387.88M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H's stock has declined approximately 28.44% over the past 52 weeks. The 50-day moving average sits at 5.70, while the 200-day moving average is 6.23.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H generated 10.29B in revenue and converted that into 387.88M in net income, yielding earnings per share of 0.29. EBITDA reached 494.86M, while operating income came in at 587.16M.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H holds 1.45B in cash and equivalents against 1.61B in total debt, resulting in a net debt position of 136.93M. Total book value stands at 6.08B, with working capital of 1.99B providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H posted a gross margin of 18.98, reflecting its pricing power and cost economics. The operating margin of 5.71 and net profit margin of 3.77 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H paid dividends of 0.03 per share. The dividend payout ratio of 9.93 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.56, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shandong Xinhua Pharmaceutical Company Limited Class H shareholders.

Shandong Xinhua Pharmaceutical Company Limited Class H's most recent stock split took place on July 6, 2018 with a 10:13 split ratio.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Company Limited Class H has an Altman Z-Score of 3.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.